炎症性肠道疾病的双重向治疗的有效性和安全性:在中国进行的一项回顾性多中心研究

相关实验视频

Updated: May 7, 2025

06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

756

Xiuxiu Jin^1,2, Kefang Sun¹, Liying Wang³

¹Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

Therapeutic advances in gastroenterology

|January 6, 2025

概括

结合生物药物和小分子,为耐火性炎症性肠病 (IBD) 和相关疾病提供了有效和安全的治疗方法. 这种双重向疗法在获得临床和内镜缓解方面显示出有希望的结果,对于选择有限的患者来说.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

对于耐火性炎症性肠病 (IBD) 存在有限的治疗选择.
同时的IBD和肠外表现 (EIM) 存在治疗挑战.
活性免疫媒介性炎症性疾病 (IMID) 进一步复杂化了患者的管理.

研究的目的:

评估在耐火性IBD患者中双重向治疗的疗效和安全性.
评估在患有活性EIM的患者中结合生物药物或小分子的有效性.
检查有活跃IMID的患者的组合治疗结果.

主要方法:

对47名接受双重向治疗的IBD患者进行了回顾性多中心研究.
从2022年1月到2024年6月收集的人口统计,疾病特征和治疗结果的数据.
主要终点:临床缓解 (哈维-布拉德肖指数/患者报告的结果2) ≥4个月;次要终点:临床/内镜反应/缓解,不良事件.

主要成果:

78.7%的人获得了临床响应,57.4%的人获得了临床缓解,随访时间中位数为13.0个月.
在29名接受内镜随访的患者中,51.7%实现了内镜反应,27.6%实现了内镜缓解.
17名患者 (36.2%) 经历了轻度/中度不良事件,1名患者 (2.1%) 经历了严重不良事件.

结论:

与生物药物和小分子的联合治疗对耐火性IBD有效.
双重向治疗在同时患有EIM/IMID的患者中显示出安全性.
这种方法为复杂的炎症性肠病病例提供了可行的治疗策略.

关键词:

生物学是生物学的学科.组合组合组合的组合组合.炎症性肠病是一种炎症性肠病.小分子的小分子.

相关概念视频

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

02:57

Targeted Cancer Therapies

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.4K

01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

218

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

218

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...